Coronavirus Disease-2019 Case, Death, and Testing Rates in the United States and Worldwide: Primary Data and Review

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

not a clinical trial

Funding Statement

Support for this research was received from Boston Heart Diagnostics, Viracor-Eurofins Clinical Diagnostics and Scientific Network, Diatherix, and Trinity Health of New England. Many of the authors are either full-time or part-time employees of the reference laboratories supporting this study, that provide testing for healthcare providers. No payments were received from any third party to influence the results of the research.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All subject information was anonymized prior to data analysis, and all relevant ethical guidelines were followed. We have followed the STROBE Guidelines for Observation Studies. IRB oversight for patient data extracted from medical records without name or identification number and analyzed as anonymized data was provided by Advarra Institutional Review Board (Columbia, MD). As stated in the cover letter and in the manuscript, the determination of the Advisory Review dated 25. September 2020 was "had the request for exempt determination been submitted prior to initiation of research activities, the research would have met the criteria for exemption from IRB review under 45 CFR 46.104(d)(4)." The study population included a subset of 91 previously diagnosed COVID-19 subjects who were being evaluated as potential participants in an approved human IRB protocol at Trinity Health of New England (Hartford, CT).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes